Orexigen Submits Contrave Marketing Authorization Application to EMA
October 03, 2013 at 07:06 AM EDT
Orexigen Therapeutics (NASDAQ: OREX ) today announced that the company has submitted the Marketing Authorization Application (MAA) for Contrave® to the European Medicines Agency (EMA) utilizing the EMA's Centralized Procedure. Orexigen is seeking approval for Contrave (32 mg naltrexone sustained release (SR) / 360 mg bupropion SR) for the
